EIKN
NASDAQ HealthcareEikon Therapeutics, Inc. - Common Stock
Biotechnology
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
๐ Market Data
| Price | $9.68 |
|---|---|
| Volume | 158,047 |
| Market Cap | 524.06M |
| RSI (14-Day) | 48.6 |
| 50-Day MA | $11.59 |
| 52-Week High | $17.40 |
| 52-Week Low | $7.90 |
| Forward P/E | -1.71 |
| Price / Book | -0.03 |
๐ฏ Investment Strategy Scores
EIKN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (64/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (14/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EIKN in your text
Paste any article, transcript, or post โ the tool will extract EIKN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.